Oncology Questions? Ask an Oncologist for Answers ASAP
There are no clinical trials that have established the optimal regimen for concurrent chemoradiotherapy. Widely used regimens include a full dose combination of cisplatin plus etoposide, in conjunction with once daily RT to a dose of approximately 60 Gy, which is followed by two additional cycles of cisplatin plus etoposide. An alternative “radiosensitizing chemotherapy” approach uses weekly carboplatin plus paclitaxel with approximately 60 Gy of radiation, follow by two cycles of consolidation with this same chemotherapy combination at standard doses. Agents that target the epidermal growth factor receptor (EGFR) pathway are being studied in combination with chemotherapy and radiotherapy for patients with unresectable stage III NSCLC. Targeted therapy is not indicated outside of a clinical trial for patients with unresectable stage III NSCLC.